## Vikash Kumar Dubey

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1102006/publications.pdf Version: 2024-02-01



#	Article	lF	CITATIONS
1	Targeting two potential sites of SARS-CoV-2 main protease through computational drug repurposing. Journal of Biomolecular Structure and Dynamics, 2023, 41, 3014-3024.	3.5	5
2	Virtual screening and repurposing of FDA-approved drugs from ZINC database to identify potential autophagy inhibitors exploiting autophagy related 4A cysteine peptidase as a target: potential as novel anti-cancer molecule Journal of Biomolecular Structure and Dynamics, 2022, 40, 5266-5282.	3.5	3
3	Repurposing of FDA-approved drugs as autophagy inhibitors in tumor cells. Journal of Biomolecular Structure and Dynamics, 2022, 40, 5815-5826.	3.5	4
4	Synthesis and characterization of zinc derivatized 3, 5-dihydroxy 4′, 7-dimethoxyflavone and its anti leishmaniasis activity against Leishmania donovani. BioMetals, 2022, 35, 285-301.	4.1	3
5	Beclin1-mediated interplay between autophagy and apoptosis: New understanding. International Journal of Biological Macromolecules, 2022, 204, 258-273.	7.5	45
6	Bacterial protein azurin and derived peptides as potential anti-SARS-CoV-2 agents: insights from molecular docking and molecular dynamics simulations. Journal of Biomolecular Structure and Dynamics, 2021, 39, 5706-5721.	3.5	18
7	Interaction of selected biomolecules and metabolites with amyloidogenic proteins. Journal of Biomolecular Structure and Dynamics, 2021, 39, 1-10.	3.5	9
8	IFN-γ+ CD4+T cell-driven prophylactic potential of recombinant LDBPK_252400 hypothetical protein of Leishmania donovani against visceral leishmaniasis. Cellular Immunology, 2021, 361, 104272.	3.0	6
9	Molecular docking, binding mode analysis, molecular dynamics, and prediction of ADMET/toxicity properties of selective potential antiviral agents against SARS-CoV-2 main protease: an effort toward drug repurposing to combat COVID-19. Molecular Diversity, 2021, 25, 1905-1927.	3.9	29
10	Purines and Pyrimidines: Metabolism, Function and Potential as Therapeutic Options in Neurodegenerative Diseases. Current Protein and Peptide Science, 2021, 22, 170-189.	1.4	6
11	Identification of high affinity and low molecular alternatives of boceprevir against SARS-CoV-2 main protease: A virtual screening approach. Chemical Physics Letters, 2021, 770, 138446.	2.6	14
12	Potential alternatives to current cholinesterase inhibitors: an <i>in silico</i> drug repurposing approach. Drug Development and Industrial Pharmacy, 2021, 47, 919-930.	2.0	17
13	Structure-guided approach to identify a novel class of anti-leishmaniasis diaryl sulfide compounds targeting the trypanothione metabolism. Amino Acids, 2020, 52, 247-259.	2.7	15
14	Fabrication of nanoparticles from a synthesized peptide amphiphile as a versatile therapeutic cargo for high antiproliferative activity in tumor cells. Bioorganic Chemistry, 2020, 94, 103440.	4.1	6
15	Mutational studies on Leishmania donovani dihydrolipoamide dehydrogenase (LdBPK291950.1) indicates that the enzyme may not be classical class-I pyridine nucleotide-disulfide oxidoreductase. International Journal of Biological Macromolecules, 2020, 164, 2141-2150.	7.5	1
16	Design of a multi-epitope subunit vaccine for immune-protection against Leishmania parasite. Pathogens and Global Health, 2020, 114, 471-481.	2.3	29
17	BLIMP-1 Mediated Downregulation of TAK1 and p53 Molecules Is Crucial in the Pathogenesis of Kala-Azar. Frontiers in Cellular and Infection Microbiology, 2020, 10, 594431.	3.9	4
18	Identification of new anti-nCoV drug chemical compounds from Indian spices exploiting SARS-CoV-2 main protease as target. Journal of Biomolecular Structure and Dynamics, 2020, , 1-9.	3.5	132

#	Article	IF	CITATIONS
19	Advances in protein misfolding, amyloidosis and its correlation with human diseases. 3 Biotech, 2020, 10, 193.	2.2	15
20	Review on natural products as an alternative to contemporary anti-leishmanial therapeutics. Journal of Proteins and Proteomics, 2020, 11, 135-158.	1.5	17
21	Identification of lead molecules against potential drug target protein MAPK4 from L. donovani: An in-silico approach using docking, molecular dynamics and binding free energy calculation. PLoS ONE, 2019, 14, e0221331.	2.5	39
22	BLIMP-1 Plays Important Role in the Regulation of Macrophage Pyroptosis for the Growth and Multiplication of <i>Leishmania donovani</i> . ACS Infectious Diseases, 2019, 5, 2087-2095.	3.8	10
23	Folding and stability of recombinant azoreductase enzyme from Chromobacterium violaceum. Enzyme and Microbial Technology, 2019, 131, 109433.	3.2	2
24	Biochemical characterization and chemical validation of Leishmania MAP Kinase-3 as a potential drug target. Scientific Reports, 2019, 9, 16209.	3.3	17
25	Homologous overexpression of hydrogenase and glycerol dehydrogenase in Clostridium pasteurianum to enhance hydrogen production from crude glycerol. Bioresource Technology, 2019, 284, 168-177.	9.6	30
26	Leishmania donovani evades Caspase 1 dependent host defense mechanism during infection. International Journal of Biological Macromolecules, 2019, 126, 392-401.	7.5	13
27	Biochemical characterization of a stable azoreductase enzyme from Chromobacterium violaceum: Application in industrial effluent dye degradation. International Journal of Biological Macromolecules, 2019, 121, 1011-1018.	7.5	35
28	Episomal expression of human glutathione reductase (HuGR) in Leishmania sheds light on evolutionary pressure for unique redox metabolism pathway: Impaired stress tolerance ability of Leishmania donovani. International Journal of Biological Macromolecules, 2019, 121, 498-507.	7.5	2
29	Dihydrolipoamide dehydrogenase from Leishmania donovani: New insights through biochemical characterization. International Journal of Biological Macromolecules, 2018, 112, 1241-1247.	7.5	5
30	Fresh insights into the pyrimidine metabolism in the trypanosomatids. Parasites and Vectors, 2018, 11, 87.	2.5	17
31	Leishmania donovani asparaginase variants exhibit cytosolic localization. International Journal of Biological Macromolecules, 2018, 114, 35-39.	7.5	4
32	Synthesis and Evaluation of Methyl 4-(7-Hydroxy-4,4,8-Trimethyl-3-Oxabicyclo[3.3.1]Nonan-2-yl)Benzoate as an Antileishmanial Agent and Its Synergistic Effect with Miltefosine. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	4
33	Identification of two natural compound inhibitors of <i>Leishmania donovani</i> Spermidine Synthase (SpdS) through molecular docking and dynamic studies. Journal of Biomolecular Structure and Dynamics, 2018, 36, 2678-2693.	3.5	14
34	Apoptosis: Mediator Molecules, Interplay with Other Cell Death Processes and Therapeutic Potentials. Current Pharmaceutical Biotechnology, 2018, 19, 644-663.	1.6	27
35	Design of commercially comparable nanotherapeutic agent against human disease-causing parasite, Leishmania. Scientific Reports, 2018, 8, 8814.	3.3	34
36	Geobacillus yumthangensis sp. nov., a thermophilic bacterium isolated from a north-east Indian hot spring. International Journal of Systematic and Evolutionary Microbiology, 2018, 68, 3430-3434.	1.7	30

#	Article	IF	CITATIONS
37	Surface-Modified Liposomal Formulation of Amphotericin B: In vitro Evaluation of Potential Against Visceral Leishmaniasis. AAPS PharmSciTech, 2017, 18, 710-720.	3.3	9
38	Evaluation of CAAX prenyl protease II of Leishmania donovani as potential drug target: Infectivity and growth of the parasite is significantly lowered after the gene knockout. European Journal of Pharmaceutical Sciences, 2017, 102, 156-160.	4.0	6
39	Molecular events leading to death of <i>Leishmania donovani</i> under spermidine starvation after hypericin treatment. Chemical Biology and Drug Design, 2017, 90, 962-971.	3.2	8
40	Methionine aminopeptidase 2 is a key regulator of apoptotic like cell death in Leishmania donovani. Scientific Reports, 2017, 7, 95.	3.3	20
41	Metabolic flux network analysis of hydrogen production from crude glycerol by Clostridium pasteurianum. Bioresource Technology, 2017, 242, 169-177.	9.6	46
42	Exploration of New and Potent Lead Molecules Against CAAX Prenyl Protease I of Leishmania donovani Through Pharmacophore Based Virtual Screening Approach. Combinatorial Chemistry and High Throughput Screening, 2017, 20, 255-271.	1.1	5
43	Biochemical characterization of dihydroorotase of Leishmania donovani: Understanding pyrimidine metabolism through its inhibition. Biochimie, 2016, 131, 45-53.	2.6	9
44	Novel Inhibitors of Ornithine Decarboxylase of <i>Leishmania</i> Parasite ( <i>Ld</i> <scp>ODC</scp> ): The Parasite Resists <i>Ld</i> <scp>ODC</scp> Inhibition by Overexpression of Spermidine Synthase. Chemical Biology and Drug Design, 2016, 87, 352-360.	3.2	19
45	Multiwalled Carbon Nanotube-Superoxide Dismutase Conjugate Towards Alleviating Induced Oxidative Stress. International Journal of Peptide Research and Therapeutics, 2016, 22, 171-177.	1.9	10
46	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	9.1	4,701
47	Molecular docking and structure-based virtual screening studies of potential drug target, CAAX prenyl proteases, of <i>Leishmania donovani</i> . Journal of Biomolecular Structure and Dynamics, 2016, 34, 2367-2386.	3.5	26
48	Understanding the importance of conservative hypothetical protein LdBPK_070020 in Leishmania donovani and its role in subsistence of the parasite. Archives of Biochemistry and Biophysics, 2016, 596, 10-21.	3.0	4
49	Quantitative Proteome Analysis of Leishmania donovani under Spermidine Starvation. PLoS ONE, 2016, 11, e0154262.	2.5	10
50	Antileishmanial Activity of Labdane Diterpenes Isolated from Alpinia nigra Seeds. Letters in Drug Design and Discovery, 2016, 13, 1-1.	0.7	6
51	Subcellular localization studies of LdBPK_070020, a conserved protein of. Journal of Vector Borne Diseases, 2016, 53, 375-378.	0.4	1
52	Novel Agents against Miltefosine-Unresponsive Leishmania donovani. Antimicrobial Agents and Chemotherapy, 2015, 59, 7826-7829.	3.2	7
53	Probing the Molecular Mechanism of Hypericin-Induced Parasite Death Provides Insight into the Role of Spermidine beyond Redox Metabolism in Leishmania donovani. Antimicrobial Agents and Chemotherapy, 2015, 59, 15-24.	3.2	31
54	Ornithine decarboxylase of <i>Leishmania donovani:</i> Biochemical Properties and Possible Role of N-Terminal Extension. Protein and Peptide Letters, 2015, 22, 130-136.	0.9	5

#	Article	IF	CITATIONS
55	An insight into plant lipase research – challenges encountered. Protein Expression and Purification, 2014, 95, 13-21.	1.3	52
56	Discovery of novel anti-leishmanial agents targeting LdLip3 lipase. Journal of Molecular Graphics and Modelling, 2014, 49, 68-79.	2.4	8
57	Emulating structural stability of Pseudomonas mendocina lipase: in silico mutagenesis and molecular dynamics studies. Journal of Molecular Modeling, 2014, 20, 2501.	1.8	3
58	Molecular Mechanisms of In vitro Betulin-Induced Apoptosis of Leishmania donovani. American Journal of Tropical Medicine and Hygiene, 2014, 90, 354-360.	1.4	28
59	Carbon nanotube based betulin formulation shows better efficacy against Leishmania parasite. Parasitology International, 2014, 63, 772-776.	1.3	28
60	Procerain B, a cysteine protease from Calotropis procera, requires N-terminus pro-region for activity: cDNA cloning and expression with pro-sequence. Protein Expression and Purification, 2014, 103, 16-22.	1.3	7
61	In Vivo Assessment of Antileishmanial Property of 4-(4,4,8-Trimethyl-7-) Tj ETQq1 1 0.784314 rgBT /Overlock Drug Design and Discovery, 2014, 11, 937-939.	10 Tf 50 507 <sup>-</sup> 0 <b>.</b> 7	Td (oxo-3-axa 5
62	SDS Induced Refolding of Pre-molten Globule State of Cryptolepain: Differences in Chemical and Temperature-Induced Equilibrium Unfolding of the Protein in SDS-Induced State. Proceedings of the National Academy of Sciences India Section B - Biological Sciences, 2013, 83, 71-80.	1.0	2
63	Molecular mechanism underlying antileishmanial effect of oxabicyclo[3.3.1]nonanones: Inhibition of key redox enzymes of the pathogen. European Journal of Pharmaceutics and Biopharmaceutics, 2013, 85, 569-577.	4.3	48
64	Exploring critical determinants of protein amyloidogenesis: a review. Journal of Peptide Science, 2013, 19, 529-536.	1.4	16
65	Biodegradable Polycaprolactone (PCL) Nanosphere Encapsulating Superoxide Dismutase and Catalase Enzymes. Applied Biochemistry and Biotechnology, 2013, 171, 1545-1558.	2.9	16
66	Miltefosineâ€unresponsive <i><scp>L</scp>eishmaniaÂdonovani</i> has a greater ability than miltefosineâ€responsive <i><scp>L</scp>.Âdonovani</i> to resist reactive oxygen species. FEBS Journal, 2013, 280, 4807-4815.	4.7	52
67	Studies on ornithine decarboxylase of Leishmania donovani: structure modeling and inhibitor docking. Medicinal Chemistry Research, 2013, 22, 466-478.	2.4	13
68	Evaluation of a diospyrin derivative as antileishmanial agent and potential modulator of ornithine decarboxylase of Leishmania donovani. Experimental Parasitology, 2013, 135, 407-413.	1.2	31
69	cDNA Cloning and Molecular Modeling of Procerain B, a Novel Cysteine Endopeptidase Isolated from Calotropis procera. PLoS ONE, 2013, 8, e59806.	2.5	15
70	Immobilization of Procerain B, a Cysteine Endopeptidase, on Amberlite MB-150 Beads. PLoS ONE, 2013, 8, e66000.	2.5	9
71	A Novel Superoxide Dismutase from Cicer arietinum L. Seedlings: Isolation, Purification and Characterization. Protein and Peptide Letters, 2013, 20, 741-748.	0.9	9
72	Nanospheres Encapsulating Anti-Leishmanial Drugs for Their Specific Macrophage Targeting, Reduced Toxicity, and Deliberate Intracellular Release. Vector-Borne and Zoonotic Diseases, 2012, 12, 953-960.	1.5	11

#	Article	IF	CITATIONS
73	Mechanistic insights into the dual inhibition strategy for checking Leishmaniasis. Journal of Biomolecular Structure and Dynamics, 2012, 30, 474-487.	3.5	5
74	Evaluating Quinacrine as a Potential Amyloid Imaging Compound: Studies on Hen Egg White Lysozyme as Model System. Protein and Peptide Letters, 2012, 19, 826-831.	0.9	4
75	A leishmaniasis study: Structure-based screening and molecular dynamics mechanistic analysis for discovering potent inhibitors of spermidine synthase. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2012, 1824, 1476-1483.	2.3	34
76	Iridoid glucosides from Nyctanthes arbortristis result in increased reactive oxygen species and cellular redox homeostasis imbalance in Leishmania parasite. European Journal of Medicinal Chemistry, 2012, 54, 49-58.	5.5	48
77	Targeting essential cell wall lipase Rv3802c for potential therapeutics against tuberculosis. Journal of Molecular Graphics and Modelling, 2012, 38, 235-242.	2.4	8
78	Blocking Protein kinase C signaling pathway: mechanistic insights into the anti-leishmanial activity of prospective herbal drugs from Withania somnifera. BMC Genomics, 2012, 13, S20.	2.8	20
79	Footprinting of Inhibitor Interactions of <i>In Silico</i> Identified Inhibitors of Trypanothione Reductase of <i>Leishmania</i> Parasite. Scientific World Journal, The, 2012, 2012, 1-13.	2.1	14
80	Effectivity of anti-oxidative enzymatic system on diminishing the oxidative stress induced by aluminium in chickpea (Cicer arietinum L.) seedlings. Brazilian Journal of Plant Physiology, 2012, 24, 47-54.	0.5	17
81	Molecular Docking and in Vitro Antileishmanial Evaluation of Chromene-2-thione Analogues. ACS Medicinal Chemistry Letters, 2012, 3, 243-247.	2.8	50
82	Unraveling the Rationale Behind Organic Solvent Stability of Lipases. Applied Biochemistry and Biotechnology, 2012, 167, 439-461.	2.9	39
83	Potential Selective Inhibitors against Rv0183 of <i>Mycobacterium tuberculosis</i> Targeting Host Lipid Metabolism. Chemical Biology and Drug Design, 2012, 79, 1056-1062.	3.2	12
84	Evaluation of plumbagin and its derivative as potential modulators of redox thiol metabolism of Leishmania parasite. Parasitology Research, 2012, 110, 341-348.	1.6	40
85	Epitopic analysis of Potential Vaccine Candidate in Leishmania infantum for Development of Human Vaccine. Letters in Drug Design and Discovery, 2012, 9, 698-705.	0.7	1
86	Glutaraldehyde-Activated Chitosan Matrix for Immobilization of a Novel Cysteine Protease, Procerain B. Journal of Agricultural and Food Chemistry, 2011, 59, 6256-6262.	5.2	88
87	Effect of sodium tetrathionate on amyloid fibril: Insight into the role of disulfide bond in amyloid progression. Biochimie, 2011, 93, 962-968.	2.6	29
88	Rottlerin dissolves pre-formed protein amyloid: A study on hen egg white lysozyme. Biochimica Et Biophysica Acta - General Subjects, 2011, 1810, 809-814.	2.4	23
89	Deciphering molecular mechanism underlying antileishmanial activity of Nyctanthes arbortristis, an Indian medicinal plant. Journal of Ethnopharmacology, 2011, 134, 996-998.	4.1	28
90	Evaluation of selected antitumor agents as subversive substrate and potential inhibitor of trypanothione reductase: an alternative approach for chemotherapy of Leishmaniasis. Molecular and Cellular Biochemistry, 2011, 352, 261-270.	3.1	42

#	Article	IF	CITATIONS
91	In silico characterization of thermostable lipases. Extremophiles, 2011, 15, 89-103.	2.3	25
92	Purification, characterization and immobilization of urease from Momordica charantia seeds. Process Biochemistry, 2011, 46, 1486-1491.	3.7	28
93	Exploring Applications of Procerain B, a Novel Protease from Calotropis procera, and Characterization by N-Terminal Sequencing as well as Peptide Mass Fingerprinting. Applied Biochemistry and Biotechnology, 2011, 164, 573-580.	2.9	22
94	Biophysical and Folding Parameters of Trypanothione Reductase from Leishmania infantum. Applied Biochemistry and Biotechnology, 2011, 165, 13-23.	2.9	1
95	Screening natural products database for identification of potential antileishmanial chemotherapeutic agents. Interdisciplinary Sciences, Computational Life Sciences, 2011, 3, 217-231.	3.6	17
96	Exploring possibility of promiscuity of amyloid inhibitor: Studies on effect of selected compounds on folding and amyloid formation of proteins. Process Biochemistry, 2011, 46, 1179-1185.	3.7	16
97	Cloning, expression, characterization and inhibition studies on trypanothione synthetase, a drug target enzyme, from Leishmania donovani. Biological Chemistry, 2011, 392, 1113-1122.	2.5	40
98	In Silico Characterization of Thermoactive, Alkaline and Detergent-Stable Lipase from a Staphylococcus Aureus Strain. In Silico Biology, 2010, 10, 265-276.	0.9	1
99	Purification of a novel cysteine protease, procerain B, from Calotropis procera with distinct characteristics compared to procerain. Process Biochemistry, 2010, 45, 399-406.	3.7	44
100	Rational Approaches for Drug Designing Against Leishmaniasis. Applied Biochemistry and Biotechnology, 2010, 160, 2208-2218.	2.9	45
101	Insights into pH-Induced Conformational Transition of β-Galactosidase from Pisum sativum Leading to its Multimerization. Applied Biochemistry and Biotechnology, 2010, 162, 2294-2312.	2.9	7
102	Molecular docking studies of selected tricyclic and quinone derivatives on trypanothione reductase of <i>Leishmania infantum</i> . Journal of Computational Chemistry, 2010, 31, 2463-2475.	3.3	52
103	Mitogen-activated protein kinase 4 of Leishmania parasite as a therapeutic target. European Journal of Medicinal Chemistry, 2010, 45, 5662-5670.	5.5	12
104	Protein Nano-Fibrilar Structure and Associated Diseases. Current Proteomics, 2010, 7, 116-120.	0.3	10
105	Database of in silico Predicted Potential Drug Target Proteins in Common Bacterial Human Pathogens. American Journal of Drug Discovery and Development, 2010, 1, 70-74.	0.6	8
106	In Silico Studies on Tryparedoxin Peroxidase of Leishmania infantum: Structural Aspects. Current Pharmaceutical Biotechnology, 2009, 10, 626-630.	1.6	7
107	Identification of Potential Drug Targets of Leishmania infantum by In-silico Genome Analysis. Letters in Drug Design and Discovery, 2009, 6, 620-622.	0.7	9
108	Stability and unfolding studies on alkaline denatured state (Ip) of pepsin. Process Biochemistry, 2009, 44, 906-911.	3.7	12

#	Article	IF	CITATIONS
109	Biophysical Characterization and Folding Studies of Plant Protease, Wrightin: Identification of Folding Intermediate Under Different Conditions. Protein Journal, 2009, 28, 213-223.	1.6	4
110	A simple method based on multiple alignment and phylogeny to derive a correlation between the protein fold and sequence via motif search. Interdisciplinary Sciences, Computational Life Sciences, 2009, 1, 235-243.	3.6	0
111	Effect of alkyl alcohols on partially unfolded state of Proteinase K: Differential stability of α-helix and β-sheet rich regions of the enzyme. Biochimie, 2009, 91, 951-960.	2.6	17
112	Effect of curcumin on amyloidogenic property of molten globule-like intermediate state of 2,5-diketo-d-gluconate reductase A. Biological Chemistry, 2009, 390, 1057-1061.	2.5	15
113	Understanding the Language of Vitamin C. Current Nutrition and Food Science, 2009, 5, 53-55.	0.6	6
114	A Logical OR Redundancy within the Asx-Pro-Asx-Gly Type I β-Turn Motif. Journal of Molecular Biology, 2008, 377, 1251-1264.	4.2	24
115	Roles for Cavities in Protein Structure: New Insights. Current Proteomics, 2008, 5, 157-160.	0.3	6
116	Biophysical Characterization of Fibroblast Growth Factor Homologous Factor-1b (FHF-1b): Sodium Dodecyl Sulfate Promotes Two State Folding. Protein and Peptide Letters, 2008, 15, 215-218.	0.9	2
117	Modeled structure of trypanothione reductase of Leishmania infantum. BMB Reports, 2008, 41, 444-447.	2.4	32
118	Accumulation of partly folded states in the equilibrium unfolding of ervatamin A: Spectroscopic description of the native, intermediate, and unfolded states. Biochimie, 2007, 89, 1416-1424.	2.6	19
119	Spackling the Crack: Stabilizing Human Fibroblast Growth Factor-1 by Targeting the N and C terminus β-Strand Interactions. Journal of Molecular Biology, 2007, 371, 256-268.	4.2	31
120	A Novel Serine Protease Cryptolepain fromCryptolepis buchanani:Â Purification and Biochemical Characterization. Journal of Agricultural and Food Chemistry, 2006, 54, 10141-10150.	5.2	54
121	Snapshots of Protein Folding Problem: Implications of Folding and Misfolding Studies. Protein and Peptide Letters, 2006, 13, 883-888.	0.9	3
122	Effect of Organic Solvents on the Molten Globule State of Procerain: β-Sheet to α-Helix Switchover in Presence of Trifluoroethanol. Protein and Peptide Letters, 2006, 13, 545-547.	0.9	14
123	Redesigning symmetry-related "mini-core―regions of FGF-1 to increase primary structure symmetry: Thermodynamic and functional consequences of structural symmetry. Protein Science, 2005, 14, 2315-2323.	7.6	23
124	Conversion of type I 4:6 to 3:5 Î <sup>2</sup> -turn types in human acidic fibroblast growth factor: Effects upon structure, stability, folding, and mitogenic function. Proteins: Structure, Function and Bioinformatics, 2005, 62, 686-697.	2.6	5
125	An Obligatory Intermediate in the Folding Pathway of Cytochromec552 from Hydrogenobacterthermophilus. Journal of Biological Chemistry, 2005, 280, 25729-25734.	3.4	68
126	Symmetric Primary and Tertiary Structure Mutations within a Symmetric Superfold: A Solution, not a Constraint, to Achieve a Foldable Polypeptide. Journal of Molecular Biology, 2004, 344, 769-780.	4.2	34

#	Article	IF	CITATIONS
127	Unfolding of Ervatamin C in the Presence of Organic Solvents: Sequential Transitions of the Protein in the O-state. BMB Reports, 2004, 37, 586-596.	2.4	7
128	Procerain, a stable cysteine protease from the latex of Calotropis procera. Phytochemistry, 2003, 62, 1057-1071.	2.9	131
129	Differences in the Unfolding of Procerain Induced by pH, Guanidine Hydrochloride, Urea, and Temperatureâ€. Biochemistry, 2003, 42, 12287-12297.	2.5	65